Illinois is currently home to 2638 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Chicago, Peoria, Springfield and Urbana. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
NCT05283330
Recruiting
A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or Metastatic GRPR-expressing Tumors
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: Northwestern University Robert H Lurie Medical Research, Chicago, Illinois
Conditions: Cervical Cancer, Prostate Cancer Metastatic, Breast Cancer, Colon Cancer, NSCLC, Cutaneous Melanoma
Register for Updates
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
NCT05211895
Recruiting
This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) and domvanalimab (AB154) compared with durvalumab plus placebo in adults with locally advanced (Stage III), unresectable NSCLC whose disease has not progressed following definitive platinum-based cCRT.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: Research Site, Elmhurst, Illinois
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
NCT05156398
Recruiting
The purpose of this study is to compare the efficacy and safety of rimegepant to placebo as a preventative treatment for migraine in children and adolescents ≥ 6 to \<18 years with episodic migraine.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
06/23/2025
Locations: Diamond Headache Clinic, Chicago, Illinois
Conditions: Migraine
Register for Updates
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
NCT05100862
Recruiting
The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R\^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free survival as determined by an independent review committee in accordance with the 2014 modification of the International Working Group on non-Hodgkin lymphoma (NHL) Criteria based on n positron emission tomography and computed tomography (PET/CT), and to compare the e... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: Cancer Care Specialists of Illinois, Decatur, Illinois
Conditions: Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma
Register for Updates
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
NCT05006716
Recruiting
Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: Midwestern Regional Medical Center, Zion, Illinois
Conditions: B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-hodgkin Lymphoma, Waldenström Macroglobulinemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma
Register for Updates
Subcutaneous Progesterone in Frozen- Thawed Single Euploid Blastocyst Transfer.
NCT04549116
Recruiting
This is a multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority clinical study in women aged 35 to 42 years. This study will investigate the safety and efficacy of Progesterone-IBSA to support euploid embryo blastocyst implantation and early pregnancy after frozen embryo transfer (FET) in a modified natural cycle as a treatment for infertile women. Subjects will be randomized to receive either active Progesterone-IBSA or Crinone 8% for luteal and early pregnancy... Read More
Gender:
FEMALE
Ages:
Between 35 years and 42 years
Trial Updated:
06/23/2025
Locations: InVia Fertility Specialists, PLLP, Hoffman Estates, Illinois
Conditions: Infertility
Register for Updates
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
NCT04389632
Recruiting
This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study whether sigvotatug vedotin works to treat solid tumors. The study will have four parts. * Part A of the study will find out how much sigvotatug vedoti... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: Ingalls Family Care Center, Calumet City, Illinois
Conditions: Cutaneous Squamous Cell Cancer, Exocrine Pancreatic Adenocarcinoma, Carcinoma, Non-small Cell Lung, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Ovarian Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Stomach Neoplasms, HER2 Negative Breast Neoplasms, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Register for Updates
Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
NCT04262206
Recruiting
PREVENTABLE is a multi-center, randomized, parallel group, placebo-controlled superiority study. Participants will be randomized 1:1 to atorvastatin 40 mg or placebo. This large study conducted in community-dwelling older adults without cardiovascular disease (CVD) or dementia will demonstrate the benefit of statins for reducing the primary composite of death, dementia, and persistent disability and secondary composites including mild cognitive impairment (MCI) and cardiovascular events.
Gender:
ALL
Ages:
75 years and above
Trial Updated:
06/23/2025
Locations: Northwestern University, Chicago, Illinois
Conditions: Cognitive Impairment, Mild, Dementia, Cardiovascular Diseases
Register for Updates
Molecular Genetics Studies of Cancer Patients and Their Relatives
NCT04185935
Recruiting
This trial studies the genetic and behavioral factors that may contribute to the development of specific cancers and how these factors may affect the outcome of the disease in patients with a history of cancer and their relatives.
Gender:
ALL
Ages:
All
Trial Updated:
06/23/2025
Locations: John H Stroger Jr Hospital of Cook County, Chicago, Illinois
Conditions: Malignant Neoplasm
Register for Updates
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
NCT03907046
Recruiting
Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: NCH Hospital, Arlington Heights, Arlington Heights, Illinois
Conditions: Intracerebral Hemorrhage, Atrial Fibrillation
Register for Updates
Testing the Anti-Cancer Drug Darolutamide in Patients With Testosterone-driven Salivary Gland Cancers
NCT05669664
Recruiting
This phase II trial tests how well darolutamide and leuprolide acetate work in treating patients with androgen receptor positive salivary cancer that has spread from where it first started (primary site) to other places in the body (metastatic), cannot be removed by surgery (unresectable) or that has come back after a period of responding to prior therapy (recurrent). Darolutamide is in a class of medications called androgen receptor inhibitors. It works by blocking the effects of androgen (a ma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/21/2025
Locations: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
Conditions: Locally Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Unresectable Salivary Gland Carcinoma
Register for Updates
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
NCT06934226
Recruiting
The main purpose of this study is to assess how well JNJ-77242113 works when compared to placebo and ustekinumab in participants with moderate to severe plaque psoriasis.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
06/20/2025
Locations: Northshore Medical Group, Skokie, Illinois
Conditions: Plaque Psoriasis
Register for Updates